AICDA and cancer: Although AID’s off-target activity at non-Ig loci has been implicated in approximately 8% of cancer cases (58), recent studies demonstrate that its non-enzymatic functions in transcriptional modulation may constitute the predominant oncogenic mechanism (22, 23).